COVID-19 clinical trials: learning from exceptions in the research chaos
暂无分享，去创建一个
[1] R. Coombes,et al. Covid-19: The inside story of the RECOVERY trial , 2020, BMJ.
[2] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[3] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[4] Louise Bowman,et al. The Magic of Randomization versus the Myth of Real-World Evidence. , 2020, The New England journal of medicine.
[5] M. Landray,et al. A decade of the Clinical Trials Transformation Initiative: What have we accomplished? What have we learned? , 2018, Clinical trials.
[6] R. Heslegrave,et al. A framework for research ethics review during public emergencies , 2010, Canadian Medical Association Journal.
[7] Wolfgang Baumgärtner,et al. Phocine Distemper in German Seals, 2002 , 2004, Emerging infectious diseases.
[8] S. Straus,et al. Clinical Trials and Novel Pathogens: Lessons Learned from SARS , 2004, Emerging infectious diseases.
[9] R Peto,et al. Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.
[10] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .